UroGen Pharma
Price & Volume
Stats
See more52W Range | $9.78-$20.70 |
Market Cap | $425.3M |
Shares Short | 6M |
Financials
See moreRevenue (12 Mos) | $89.3M |
Revenue Growth (YoY) | 20.9% |
Gross Profit (12 Mos) | $80.6M |
Diluted EPS | -$3.02 |
News
See moreYahoo Finance • 2 years ago
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
Yahoo Finance • 2 years ago
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
Yahoo Finance • 2 years ago
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript
Yahoo Finance • 2 years ago
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
About
CEO | Ms. Elizabeth A. Barrett |
Address | 400 Alexander Park Drive, Princeton, NJ, United States, 08540 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 217 |
